Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Int J Cancer. 2019 Feb 14;145(5):1221–1231. doi: 10.1002/ijc.32146

Table 3.

List of replicated metabolites inversely associated with colorectal cancera

 Discovery stage: ColoCare Study
 Replication stage: CORSA
Compound Name ID
levelb 		CRC
Mean ± SDc 		Controls
Mean ± SDc 		OR.sthd
[95% CI]		 p
valuee 		CRC
Mean ± SDc 		Controls
Mean ± SDc 		OR.sthd
[95% CI]		 p valuee
Inversely associated Leucine 1 13.98 ± 0.49 14.07 ± 0.31 0.69 [0.53; 0.87] 4.4E-03 13.86 ± 0.32 13.93 ± 0.28 0.72 [0.55; 0.93] 4.7E-02
1-methylnicotinamide 1 11.18 ± 0.68 11.33 ± 0.60 0.69 [0.53; 0.88] 6.5E-03 11.11 ± 0.45 11.36 ± 0.56 0.62 [0.46; 0.83] 6.8E-03
Valine 1 10.36 ± 0.33 10.43 ± 0.33 0.74 [0.56; 0.96] 4.2E-02 10.18 ± 0.35 10.27 ± 0.27 0.69 [0.53; 0.89] 1.7E-02
Bilirubin 1 11.54 ± 0.59 11.74 ± 0.56 0.57 [0.43; 0.75] 1.5E-04 11.66 ± 0.64 11.92 ± 0.62 0.66 [0.49; 0.87] 1.5E-02
LysoPC(16:1) 2 10.90 ± 0.35 11.02 ± 0.27 0.60 [0.46; 0.77] 1.2E-04 10.31 ± 0.46 10.44 ± 0.36 0.73 [0.57; 0.93] 4.4E-02
LysoPC(P-16:0) 2 11.58 ± 0.42 11.68 ± 0.28 0.76 [0.61; 0.94] 2.0E-02 11.63 ± 0.42 11.81 ± 0.39 0.66 [0.50; 0.87] 1.4E-02
LysoPC(15:0) 2 11.90 ± 0.49 12.19 ± 0.36 0.53 [0.40; 0.67] 2.8E-07 11.69 ± 0.48 11.83 ± 0.43 0.71 [0.55; 0.92] 4.2E-02
LysoPC (16:0) 2 16.44 ± 0.38 16.52 ± 0.13 0.75 [0.61; 0.91] 5.7E-03 16.49 ± 0.26 16.61 ± 0.19 0.59 [0.46; 0.76] 3.3E-04
LysoPC(16:0) isomer 2 14.28 ± 0.45 14.44 ± 0.21 0.71 [0.55; 0.90] 8.3E-03 14.42 ± 0.38 14.59 ± 0.30 0.58 [0.42; 0.78] 2.9E-03
LysoPC(17:0) 2 12.22 ± 0.47 12.47 ± 0.36 0.54 [0.41; 0.69] 8.9E-07 12.11 ± 0.47 12.27 ± 0.40 0.68 [0.52; 0.88] 1.7E-02
LysoPC(18:0) 2 14.84 ± 0.39 15.00 ± 0.25 0.63 [0.50; 0.78] 5.7E-05 15.00 ± 0.42 15.18 ± 0.34 0.63 [0.49; 0.81] 2.9E-03
57.1107@0.8299292 4 11.45 ± 0.65 11.44 ± 0.61 0.69 [0.52; 0.90] 1.3E-02 11.39 ± 0.68 11.52 ± 0.66 0.67 [0.49; 0.90] 3.2E-02
181.1113@5.475981 4 10.37 ± 0.51 10.75 ± 0.47 0.41 [0.30; 0.55] 5.4E-09 10.88 ± 0.42 10.95 ± 0.33 0.72 [0.55; 0.93] 4.2E-02
190.0061@0.83498704 4 10.93 ± 0.32 11.04 ± 0.24 0.61 [0.46; 0.79] 3.3E-04 11.07 ± 0.39 11.21 ± 0.32 0.66 [0.51; 0.84] 6.1E-03
247.0286@3.3104632 4 12.88 ± 0.43 13.14 ± 0.31 0.43 [0.31; 0.57] 2.6E-09 12.99 ± 0.40 13.13 ± 0.32 0.66 [0.50; 0.86] 1.2E-02
445.8809@0.56495804 4 13.86 ± 0.36 13.96 ± 0.11 0.76 [0.64; 0.90] 3.0E-03 13.79 ± 0.31 13.87 ± 0.16 0.77 [0.61; 0.94] 4.2E-02
452.8025@7.3067145 4 9.77 ± 0.26 9.85 ± 0.28 0.72 [0.54; 0.96] 4.4E-02 9.88 ± 0.23 9.97 ± 0.21 0.65 [0.50; 0.86] 1.1E-02
535.2997@7.0497603 4 11.01 ± 0.41 11.16 ± 0.35 0.65 [0.49; 0.85] 3.4E-03 11.27 ± 0.38 11.37 ± 0.33 0.72 [0.55; 0.93] 4.4E-02
545.3467@7.2500143 4 13.39 ± 0.53 13.50 ± 0.31 0.79 [0.63; 0.98] 5.0E-02 13.78 ± 0.46 14.00 ± 0.39 0.61 [0.47; 0.78] 1.1E-03
610.9343@7.191048 4 11.78 ± 0.43 11.94 ± 0.34 0.63 [0.49; 0.80] 4.6E-04 11.34 ± 0.40 11.51 ± 0.33 0.63 [0.48; 0.82] 3.9E-03
638.9663@7.4319897 4 10.85 ± 0.33 10.97 ± 0.28 0.68 [0.53; 0.87] 4.7E-03 10.98 ± 0.29 11.13 ± 0.24 0.58 [0.44; 0.76] 4.5E-04
a

Controls are defined as individuals not diagnosed with any colorectal malignancy;

b

According to MSI;

c

Log transformed relative intensity values; OR.std: standardized Odds Ratio, represents the relative change in colorectal cancer (CRC) risk when there is a one standard deviation (SD) change in metabolite intensity. OR.std is based on the SD of the controls;

e

p-value: FDR-corrected p-value